Howard J Eisen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7731198/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dietary sugar intake and risk of Alzheimer's disease in older women. Nutritional Neuroscience, 2022, 25, 2302-2313.	1.5	7
2	Novel Immunosuppression in Solid Organ Transplantation. Handbook of Experimental Pharmacology, 2022, , 1.	0.9	0
3	Something evil this way comes: Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 269-270.	0.3	0
4	CAVEAT mTOR: You've heard about the benefits of using mTOR inhibitors, here are some of the risks. American Journal of Transplantation, 2021, 21, 449-450.	2.6	2
5	Frailty in heart transplantation: Report from the heart workgroup of a consensus conference on frailty. American Journal of Transplantation, 2021, 21, 636-644.	2.6	16
6	Primum non Nocere. Transplantation, 2021, Publish Ahead of Print, .	0.5	0
7	Reply from the authors: Pseudoaneurysm after heart transplantation—Did bicuspid aortopathy contribute?. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, e128-e129.	0.4	0
8	Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. American Journal of Transplantation, 2020, 20, 2768-2780.	2.6	26
9	New French heart allocation system: Comparison with Eurotransplant and US allocation systems. American Journal of Transplantation, 2020, 20, 1236-1243.	2.6	37
10	Burden of Uncontrolled Hyperglycemia and Its Association with Patients Characteristics and Socioeconomic Status in Philadelphia, USA. Health Equity, 2020, 4, 525-532.	0.8	5
11	The Implication of Cardiac Injury Score on In-hospital Mortality of Coronavirus Disease 2019. Journal of Korean Medical Science, 2020, 35, e349.	1.1	8
12	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	1.2	37
13	mTOR inhibitors vs calcineurin inhibitors: A Catchâ€22—preventing nephrotoxicity or acute allograft rejection after heart transplantation. American Journal of Transplantation, 2019, 19, 2967-2968.	2.6	1
14	Delayed aneurysmal complication of bicuspid aortic valve disease after heart transplantation. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, e185-e186.	0.4	6
15	Assessment of pre-operative psychosocial function among people receiving left ventricular assist devices: A national survey of US LVAD programs. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 302-307.	0.8	10
16	Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications. Korean Circulation Journal, 2019, 49, 568.	0.7	36
17	Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis. Heart Failure Reviews, 2018, 23, 181-190.	1.7	15
18	The Return of the mTOR Inhibitors. Journal of the American College of Cardiology, 2018, 71, 651-653.	1.2	9

HOWARD J EISEN

#	Article	IF	CITATIONS
19	Temporal Trends of De Novo Malignancy Development After Heart Transplantation. Journal of the American College of Cardiology, 2018, 71, 40-49.	1.2	70
20	Reduced Stroke After Transcatheter Patent Foramen Ovale Closure: A Systematic Review and Meta-analysis. American Journal of the Medical Sciences, 2018, 356, 103-113.	0.4	2
21	Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2018, 30, 847-853.	0.8	15
22	Genetics of Dilated Cardiomyopathy. Current Cardiology Reports, 2018, 20, 121.	1.3	18
23	Geographic Variation in Heart Failure Mortality and Its Association With Hypertension, Diabetes, and Behavioral-Related Risk Factors in 1,723 Counties of the United States. Frontiers in Public Health, 2018, 6, 132.	1.3	27
24	Meta-Analysis Comparing Outcomes and Need for Renal Replacement Therapy of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. American Journal of Cardiology, 2018, 122, 468-476.	0.7	9
25	Ethical Considerations in the Long-Term Ventricular Assist Device Patient. Current Heart Failure Reports, 2017, 14, 7-12.	1.3	2
26	Angiotensin-Converting Enzyme Inhibitors for Cardiac Allograft Vasculopathy After Heart Transplantation â^—. Journal of the American College of Cardiology, 2017, 69, 2842-2844.	1.2	1
27	Pharmacologic Management for Heart Failure and Emerging Therapies. Current Cardiology Reports, 2017, 19, 94.	1.3	9
28	Readmission rate after ultrafiltration in acute decompensated heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2017, 22, 685-698.	1.7	14
29	Novel, More Accurate Assessments of Renal Function in Heart Transplant Patients: Commentary on â€`Chronic kidney disease after heart transplantation: a single-centre retrospective study at SkA¥ne University Hospital in Lund 1988-2010'. Transplant International, 2016, 29, 527-528.	0.8	0
30	Improvements in Dutch heart transplant patient outcomes: lessons for the future. Transplant International, 2015, 28, 960-961.	0.8	0
31	Pediatric Heart Transplant Recipients and Cardiac Allograft Vasculopathy. Journal of the American College of Cardiology, 2015, 66, 558-560.	1.2	3
32	Burden of Cardiovascular Disease among Multi-Racial and Ethnic Populations in the United States: an Update from the National Health Interview Surveys. Frontiers in Cardiovascular Medicine, 2014, 1, 8.	1.1	10
33	Use of Proliferation Signal Inhibitors in Cardiac Transplantation. Current Transplantation Reports, 2014, 1, 273-281.	0.9	3
34	Immunosuppression-state-of-the-art. Current Opinion in Organ Transplantation, 2014, 19, 500-507.	0.8	9
35	Glutathione S-Transferase Pi-1: A Novel Approach to Mitigating Adverse Cardiac Remodeling After Myocardial Infarction. Journal of Cardiac Failure, 2014, 20, 146-147.	0.7	1
36	Cardiac Allograft Vasculopathy by Intravascular Ultrasound in HeartÂTransplantÂPatients. JACC: Heart Failure, 2013, 1, 389-399.	1.9	110

HOWARD J EISEN

#	Article	IF	CITATIONS
37	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.3	1,385
38	Skeletal myoblast transplantation: no MAGIC bullet for ischemic cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 520-521.	3.3	18
39	Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis. Journal of Heart and Lung Transplantation, 2007, 26, 584-592.	0.3	107
40	Immunosuppression on the Horizon. Heart Failure Clinics, 2007, 3, 43-49.	1.0	13
41	MICRONUTRIENTS, INFLAMMATION AND CONGESTIVE HEART FAILURE AMONG THE ELDERLY: NUTRITIONAL PERSPECTIVES ON PRIMARY PREVENTION AND CLINICAL TREATMENT. Clinical and Experimental Pharmacology and Physiology, 2007, 34, S14-S16.	0.9	8
42	What can post market registries tell us about the use of cardiac resynchronization therapy?. Current Heart Failure Reports, 2007, 4, 39-42.	1.3	0
43	Long-term cardiovascular risk in transplantation—insights from the use of everolimus in heart transplantation. Nephrology Dialysis Transplantation, 2006, 21, iii9-iii13.	0.4	33
44	Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2005, 24, 517-525.	0.3	237
45	Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. New England Journal of Medicine, 2003, 349, 847-858.	13.9	1,104